{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/49451"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/49451","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Rho kinase inhibitors for the treatment of glaucoma","abstract":"Glaucoma is a degenerative disease that contributes greatly to vision loss and blindness worldwide. There are several treatments that focus on alleviating its symptoms, but few address the underlying pathophysiology, the blockage of aqueous outflow, and the onset of neuroretinal damage. Novel drugs under investigation have aimed to address this deficiency. Two of these Rho kinase inhibitors have been approved by national health agencies, and several are in clinical trials. This work investigates the promise of inhibitors of the Rho kinase signaling pathway to treat primary open-angle glaucoma.","abstract_html":"Glaucoma is a degenerative disease that contributes greatly to vision loss and blindness worldwide. There are several treatments that focus on alleviating its symptoms, but few address the underlying pathophysiology, the blockage of aqueous outflow, and the onset of neuroretinal damage. Novel drugs under investigation have aimed to address this deficiency. Two of these Rho kinase inhibitors have been approved by national health agencies, and several are in clinical trials. This work investigates the promise of inhibitors of the Rho kinase signaling pathway to treat primary open-angle glaucoma.","abstract_has_math":false,"creators":["Bekui, Seli"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Taylor, Andrew W.","Offner, Gwynneth D."],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023","date_published":"2023","updated_at":"2026-11-18T20:13:47Z","subjects":["Ophthalmology","Blindness","Glaucoma","Ocular hypertension","Rho kinase inhibitors","Visual impairment"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"dc:identifier.orcid","label":"ORCID","values":["0009-0003-9295-2681"],"render_values":[{"text":"0009-0003-9295-2681","href":"https://orcid.org/0009-0003-9295-2681","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2144/49451","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/49451","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F49451","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Taylor, Andrew W.","Offner, Gwynneth D."]},{"key":"dc:creator","label":"Author","values":["Bekui, Seli"]},{"key":"dc:identifier.orcid","label":"ORCID","values":["0009-0003-9295-2681"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2024-11-04T13:31:54Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2024-11-04T13:31:54Z"]},{"key":"dc:date.issued","label":"Date","values":["2023"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2024-10-31T01:02:49Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Ophthalmology","Blindness","Glaucoma","Ocular hypertension","Rho kinase inhibitors","Visual impairment"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/49451"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Glaucoma is a degenerative disease that contributes greatly to vision loss and blindness worldwide. There are several treatments that focus on alleviating its symptoms, but few address the underlying pathophysiology, the blockage of aqueous outflow, and the onset of neuroretinal damage. Novel drugs under investigation have aimed to address this deficiency. Two of these Rho kinase inhibitors have been approved by national health agencies, and several are in clinical trials. This work investigates the promise of inhibitors of the Rho kinase signaling pathway to treat primary open-angle glaucoma."]},{"key":"dc:title","label":"Title","values":["Rho kinase inhibitors for the treatment of glaucoma"]}]}],"canonical_facts":{"dc:contributor.advisor":["Taylor, Andrew W.","Offner, Gwynneth D."],"dc:creator":["Bekui, Seli"],"dc:date.accessioned":["2024-11-04T13:31:54Z"],"dc:date.available":["2024-11-04T13:31:54Z"],"dc:date.issued":["2023"],"dc:date.updated":["2024-10-31T01:02:49Z"],"dc:description.abstract":["Glaucoma is a degenerative disease that contributes greatly to vision loss and blindness worldwide. There are several treatments that focus on alleviating its symptoms, but few address the underlying pathophysiology, the blockage of aqueous outflow, and the onset of neuroretinal damage. Novel drugs under investigation have aimed to address this deficiency. Two of these Rho kinase inhibitors have been approved by national health agencies, and several are in clinical trials. This work investigates the promise of inhibitors of the Rho kinase signaling pathway to treat primary open-angle glaucoma."],"dc:identifier.orcid":["0009-0003-9295-2681"],"dc:identifier.uri":["https://hdl.handle.net/2144/49451"],"dc:language.iso":["en_US"],"dc:subject":["Ophthalmology","Blindness","Glaucoma","Ocular hypertension","Rho kinase inhibitors","Visual impairment"],"dc:title":["Rho kinase inhibitors for the treatment of glaucoma"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:13:47Z"}